Inogen Inc (NASDAQ:INGN) CFO Alison Bauerlein sold 11,718 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $115.87, for a total transaction of $1,357,764.66. Following the completion of the transaction, the chief financial officer now directly owns 11,718 shares of the company’s stock, valued at approximately $1,357,764.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alison Bauerlein also recently made the following trade(s):

  • On Monday, February 12th, Alison Bauerlein sold 27,630 shares of Inogen stock. The stock was sold at an average price of $116.46, for a total transaction of $3,217,789.80.

Inogen Inc (NASDAQ INGN) opened at $119.33 on Thursday. Inogen Inc has a 52 week low of $66.51 and a 52 week high of $130.05. The stock has a market capitalization of $2,450.39, a P/E ratio of 97.02, a PEG ratio of 3.98 and a beta of 1.02.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Inogen by 4.0% in the fourth quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock valued at $274,662,000 after buying an additional 87,737 shares during the period. Brown Capital Management LLC increased its stake in shares of Inogen by 1.8% in the fourth quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock valued at $269,205,000 after buying an additional 40,994 shares during the period. Vanguard Group Inc. increased its stake in shares of Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after buying an additional 301,737 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Inogen by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after buying an additional 17,111 shares during the period. Finally, State Street Corp increased its stake in shares of Inogen by 6.8% in the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after buying an additional 27,250 shares during the period.

A number of research analysts have recently commented on INGN shares. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 7th. Needham & Company LLC increased their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, BidaskClub raised shares of Inogen from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. Four research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $103.14.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/15/insider-selling-inogen-inc-ingn-cfo-sells-11718-shares-of-stock.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.